** Brokerage TD Cowen downgrades drugmaker Merck's MRK.N shares to "hold" from "buy" on weak forecast and a "lack of clarity" regarding shipment of its HPV vaccine Gardasil in China
** Last week, MRK forecast total revenues below Wall Street estimates and said it would not ship Gardasil in China until at least the middle of the year
** Lowers PT to $100 from $121 on reduced profit and sales estimates for each year through 2030
** Brokerage says MRK's business development effort seems to have lost momentum ahead of blockbuster cancer therapy Keytruda losing key patents in 2028
** Beyond Keytruda, MRK's growth story "has not improved convincingly" despite a promising pipeline of experimental treatments, brokerage says
** MRK's price to earnings ratio (P/E), a common benchmark for valuing stocks, will trough in 2026 - two years before Keytruda loses exclusivity, TD Cowen says
** Stock has fallen 24% since late July when it first disclosed Gardasil troubles
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。